Research programme: GABA A receptor inverse agonists - Roche

Drug Profile

Research programme: GABA A receptor inverse agonists - Roche

Alternative Names: L-792,782; RO; RO 4882224; RO 4938581

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Roche
  • Class Benzodiazepines
  • Mechanism of Action GABA A alpha 5 receptor inverse agonists; GABA A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cognition disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in Switzerland (PO)
  • 10 Dec 2009 Pharmacodynamics data from a preclinical trial in Cognition disorders presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009)
  • 04 Sep 2007 Preclinical trials in Cognition disorders in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top